ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2020
Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro.
Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- The role of nanofat membranes in inhibiting bacterial growth: An in vitro analysis.JPRAS open · 2026Article
- Article
- Dual-Action Regenerative Therapies: Regeneration and Antimicrobial Effects of Platelet- and Marrow-Derived Biologics.Biomedicines · 2025Review
- Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.Scientific reports · 2025Article
- Viscosupplementation and Synovial Fluid Rheology: A Hidden Risk for Bacterial Biofilm Formation in Joint Infections?Microorganisms · 2025Review
- Equine neutrophils selectively release neutrophil extracellular traps in response to chemical and bacterial agonists.Frontiers in veterinary science · 2025Article
- Plasma and complement proteins are essential for the antimicrobial activity of canine platelet lysate.Frontiers in veterinary science · 2025Article
- Antibacterial Effect of Canine Leucocyte Platelet-Rich Plasma (L-PRP) and Canine Platelet-Poor Plasma (PPP) Against Methicillin-Sensitive and Methicillin-ResistantVeterinary sciences · 2024Article
- Platelet-rich plasma intra-articular knee injections from open preparation techniques do not pose a higher risk of joint infection: A systematic review of 91 randomized controlled trials and 5914 injections.Journal of experimental orthopaedics · 2024Review
- Pilot study characterizing a single pooled preparation of equine platelet lysate for nebulization in the horse.Frontiers in veterinary science · 2024Article
- Exploring the role of bacterial virulence factors and host elements in septic arthritis: insights from animal models for innovative therapies.Frontiers in microbiology · 2024Review
- Equine bone marrow-derived mesenchymal stromal cells reduce established S. aureus and E. coli biofilm matrix in vitro.PloS one · 2024Article
- Antimicrobial Effects of Platelet-Rich Plasma and Platelet-Rich Fibrin: A Scoping Review.Cureus · 2023Article
- Antimicrobial Activity of Plasma Rich in Platelets (PRP) on the Ocular Microbiota of Healthy Horses from Minas Gerais:Veterinary medicine international · 2023Article
- Effect of BIO-PLYViruses · 2022Article
- TLR-activated mesenchymal stromal cell therapy and antibiotics to treat multi-drug resistantAnnals of translational medicine · 2022Article
- Platelet-Rich Plasma Lysate-Incorporating Gelatin Hydrogel as a Scaffold for Bone Reconstruction.Bioengineering (Basel, Switzerland) · 2022Article
- Platelet-Rich Plasma-Releasate (PRPr) for the Treatment of Discogenic Low Back Pain Patients: Long-Term Follow-Up Survey.Medicina (Kaunas, Lithuania) · 2022Article
- A Platelet-Rich Plasma-Derived Biologic ClearsFrontiers in cellular and infection microbiology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Infectious arthritis is difficult to treat in both human and veterinary clinical practice. Recent literature reports Staphylococcus aureus as well as other gram-positive and gram-negative isolates forming free-floating biofilms in both human and equine synovial fluid that are tolerant to traditional antimicrobial therapy. Using an in vitro equine model, we investigated the ability of platelet-rich plasma (PRP) formulations to combat synovial fluid biofilm aggregates. Synovial fluid was infected, and biofilm aggregates allowed to form over a 2-hour period. PRP was collected and processed into different formulations by platelet concentration, leukocyte presence, and activation or lysis. Infected synovial fluid was treated with different PRP formulations with or without aminoglycoside cotreatment. Bacterial load (colony-forming unit/mL) was determined by serial dilutions and plate counting at 8 hours posttreatment. All PRP formulations displayed antimicrobial properties; however, formulations containing higher concentrations of platelets without leukocytes had increased antimicrobial activity. Lysis of PRP and pooling of the PRP lysate (PRP-L) from multiple horses as compared to individual horses further increased antimicrobial activity. This activity was lost with the removal of the plasma component or inhibition of the proteolytic activity within the plasma. Fractionation of pooled PRP-L identified the bioactive components to be cationic and low-molecular weight (<10 kDa). Overall, PRP-L exhibited synergism with amikacin against aminoglycoside tolerant biofilm aggregates with greater activity against gram-positive bacteria. In conclusion, the use of PRP-L has the potential to augment current antimicrobial treatment regimens which could lead to a decrease in morbidity and mortality associated with infectious arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.